Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
The Motley Fool November 10, 2009 Brian Orelli	Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
Pharmaceutical Executive February 1, 2012 Ben Comer	Best to Market Pharm Exec's Brand of the Year: Abbott's Humira
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
Chemistry World June 13, 2007 James Mitchell Crow	Renewed Therapeutic Promise for Arthritis Patients Three new treatments for rheumatoid arthritis, the most common chronic inflammatory joint disease in the industrialized world, offer hope to patients where existing drugs have failed.
The Motley Fool July 29, 2011 Brian Orelli	Bristol-Myers Grows in the Wrong Places Bristol-Myers has a solid quarter, but Plavix and currency movements aren't important.
Managed Care February 2006 Thomas Morrow	New Rheumatoid Arthritis Treatment Has Potential to Reduce Payer's Costs B-cells and their markers, once overlooked in the pathophysiology of rheumatoid arthritis, may hold the key for a new treatment regimen.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool April 28, 2005 Stephen D. Simpson	Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline.
Nursing July 2011 Susan Simmons	Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.
The Motley Fool April 28, 2011 Brian Orelli	1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
The Motley Fool April 9, 2008 Brian Orelli	Repligen Gets a Surprise Infusion of Cash Bristol-Myers Squibb agrees to pay Repligen royalties in their patent-infringement lawsuit.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
Managed Care November 2005 Vogenberg, Liebeskind & Ritter	Addressing the Hidden Costs of Rheumatoid Arthritis Health plans can work directly with customers to design rheumatoid arthritis management plans that address indirect but substantial costs.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
Managed Care December 2007	Headlines on Deadline ... Health insurance for all is essential, but not enough... An Ohio House bill may require fully-insured health plans to cover treatment and diagnosis for autism... etc.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
American Family Physician October 1, 2000 Kelly W. Jones, Pharm.D. & Supen R. Patel, M.D.	A Family Physician's Guide to Monitoring Methotrexate Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy...
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool September 12, 2005 Brian Gorman	Mixed Diagnosis for Bristol-Myers Positive news on two drugs is reason to celebrate, but investors may want to keep their enthusiasm in check.
The Motley Fool February 28, 2007 Brian Lawler	Bristol-Myers Stays Out of Trouble A federal monitor finds Bristol-Myers does not have to pay up over a questionable business deal.
The Motley Fool July 31, 2006 Stephen D. Simpson	More Plavix Headaches for Bristol-Myers Problems with a Plavix settlement put a large chunk of earnings at risk. Investors, take note.
The Motley Fool July 24, 2009 Brian Orelli	Bristol-Myers: Eat or Be Eaten Bristol-Myers Squibb, the oft-rumored acquisition target of partner sanofi-aventis, is doing a little acquiring of its own, which might settle down the rumor mill.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
American Family Physician October 1, 2000	Taking the immunoinhibitor methotrexate What is methotrexate?... How do I take methotrexate?... What else should I remember about taking methotrexate?... I am a man and I want to get my partner pregnant. Can I take methotrexate?...
The Motley Fool May 1, 2007 Brian Lawler	Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note.
The Motley Fool December 14, 2004 Brian Gorman	Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.